Regenxbio Inc has a consensus price target of $40.86, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., RBC Capital, and Chardan Capital on March 11, 2024, March 8, 2024, and March 7, 2024. With an average price target of $41 between HC Wainwright & Co., RBC Capital, and Chardan Capital, there's an implied 94.59% upside for Regenxbio Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/11/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 70.86% | HC Wainwright & Co. | Yi Chen | → $36 | Initiates | → Buy | Get Alert |
03/08/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 66.11% | RBC Capital | Luca Issi | $20 → $35 | Upgrade | Sector Perform → Outperform | Get Alert |
03/07/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 146.8% | Chardan Capital | Daniil Gataulin | $52 → $52 | Maintains | Buy | Get Alert |
03/07/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 161.03% | Barclays | Gena Wang | $45 → $55 | Maintains | Overweight | Get Alert |
03/06/2024 | RGNX | Buy Now | Regenxbio | $21.07 | — | Leerink Partners | Mani Foroohar | — | Upgrade | Market Perform → Outperform | Get Alert |
03/06/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 85.1% | Baird | Brian Skorney | $34 → $39 | Maintains | Outperform | Get Alert |
02/28/2024 | RGNX | Buy Now | Regenxbio | $21.07 | -0.33% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
02/21/2024 | RGNX | Buy Now | Regenxbio | $21.07 | 113.57% | Raymond James | Dane Leone | → $45 | Reinstates | → Outperform | Get Alert |
02/12/2024 | RGNX | Buy Now | Regenxbio | $21.07 | -0.33% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
11/01/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 66.11% | Stifel | Annabel Samimy | → $35 | Initiates | → Buy | Get Alert |
10/05/2023 | RGNX | Buy Now | Regenxbio | $21.07 | -5.08% | Wedbush | Andreas Argyrides | → $20 | Reiterates | Neutral → Neutral | Get Alert |
10/04/2023 | RGNX | Buy Now | Regenxbio | $21.07 | -5.08% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
08/29/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 99.34% | Morgan Stanley | Vikram Purohit | $43 → $42 | Maintains | Overweight | Get Alert |
08/03/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 161.03% | Chardan Capital | Daniil Gataulin | → $55 | Reiterates | → Buy | Get Alert |
07/12/2023 | RGNX | Buy Now | Regenxbio | $21.07 | -5.08% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
06/20/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 99.34% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
06/02/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 99.34% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
05/09/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 104.08% | Morgan Stanley | Vikram Purohit | $46 → $43 | Maintains | Overweight | Get Alert |
05/05/2023 | RGNX | Buy Now | Regenxbio | $21.07 | 161.03% | Chardan Capital | Daniil Gataulin | $61 → $55 | Maintains | Buy | Get Alert |
The latest price target for Regenxbio (NASDAQ: RGNX) was reported by HC Wainwright & Co. on March 11, 2024. The analyst firm set a price target for $36.00 expecting RGNX to rise to within 12 months (a possible 70.86% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Regenxbio (NASDAQ: RGNX) was provided by HC Wainwright & Co., and Regenxbio initiated their buy rating.
The last upgrade for Regenxbio Inc happened on March 8, 2024 when RBC Capital raised their price target to $35. RBC Capital previously had a sector perform for Regenxbio Inc.
There is no last downgrade for Regenxbio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regenxbio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regenxbio was filed on March 11, 2024 so you should expect the next rating to be made available sometime around March 11, 2025.
While ratings are subjective and will change, the latest Regenxbio (RGNX) rating was a initiated with a price target of $0.00 to $36.00. The current price Regenxbio (RGNX) is trading at is $21.07, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.